Sea Mild Biotechnology Co., Ltd.
Sea Mild Biotechnology Co., Ltd. manufactures and sells paints, coatings, and detergents in Taiwan. It offers laundry, household, and personal detergent, as well as epidemic prevention products under the Sea Mild Biotech brand name. The company was established in 2007 is headquartered in Taoyuan City, Taiwan.
Sea Mild Biotechnology Co., Ltd. (7516) - Net Assets
Latest net assets as of June 2025: NT$107.64 Million TWD
Based on the latest financial reports, Sea Mild Biotechnology Co., Ltd. (7516) has net assets worth NT$107.64 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$281.93 Million) and total liabilities (NT$174.29 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$107.64 Million |
| % of Total Assets | 38.18% |
| Annual Growth Rate | -2.7% |
| 5-Year Change | -25.72% |
| 10-Year Change | N/A |
| Growth Volatility | 29.02 |
Sea Mild Biotechnology Co., Ltd. - Net Assets Trend (2016–2024)
This chart illustrates how Sea Mild Biotechnology Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sea Mild Biotechnology Co., Ltd. (2016–2024)
The table below shows the annual net assets of Sea Mild Biotechnology Co., Ltd. from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$102.39 Million | +45.43% |
| 2023-12-31 | NT$70.41 Million | +9.18% |
| 2022-12-31 | NT$64.48 Million | -24.86% |
| 2021-12-31 | NT$85.82 Million | -37.75% |
| 2020-12-31 | NT$137.86 Million | -28.31% |
| 2019-12-31 | NT$192.29 Million | -5.70% |
| 2018-12-31 | NT$203.91 Million | +38.62% |
| 2017-12-31 | NT$147.09 Million | +15.41% |
| 2016-12-31 | NT$127.45 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sea Mild Biotechnology Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1814900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$193.09 Million | 188.58% |
| Total Equity | NT$102.39 Million | 100.00% |
Sea Mild Biotechnology Co., Ltd. Competitors by Market Cap
The table below lists competitors of Sea Mild Biotechnology Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Stria Lithium Inc
PINK:SRCAF
|
$4.01 Million |
|
Liberty Star Uranium & Metals Corp
OTCQB:LBSR
|
$4.01 Million |
|
Eastern Technical Engineering Public Company Limited
BK:ETE
|
$4.01 Million |
|
BANK OF KIGALI
RSE:BOK
|
$4.01 Million |
|
DCM Limited
NSE:DCM
|
$4.01 Million |
|
Vicarious Surgical Inc.
NYSE:RBOT
|
$4.01 Million |
|
ZECON Bhd
KLSE:7028
|
$4.00 Million |
|
Blaize Holdings, Inc. Warrants
NASDAQ:BZAIW
|
$4.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sea Mild Biotechnology Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 70,405,000 to 102,393,000, a change of 31,988,000 (45.4%).
- Net income of 31,988,000 contributed positively to equity growth.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$31.99 Million | +31.24% |
| Total Change | NT$- | 45.43% |
Book Value vs Market Value Analysis
This analysis compares Sea Mild Biotechnology Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.75x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.13x to 1.75x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | NT$8.24 | NT$9.30 | x |
| 2017-12-31 | NT$9.51 | NT$9.30 | x |
| 2018-12-31 | NT$15.21 | NT$9.30 | x |
| 2019-12-31 | NT$10.07 | NT$9.30 | x |
| 2020-12-31 | NT$7.14 | NT$9.30 | x |
| 2021-12-31 | NT$4.44 | NT$9.30 | x |
| 2022-12-31 | NT$3.34 | NT$9.30 | x |
| 2023-12-31 | NT$3.65 | NT$9.30 | x |
| 2024-12-31 | NT$5.30 | NT$9.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sea Mild Biotechnology Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 31.24%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.03%
- • Asset Turnover: 1.24x
- • Equity Multiplier: 2.50x
- Recent ROE (31.24%) is above the historical average (-20.89%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -23.41% | -13.10% | 0.72x | 2.49x | NT$-42.58 Million |
| 2017 | 12.13% | 10.60% | 0.50x | 2.30x | NT$3.13 Million |
| 2018 | 0.03% | 0.03% | 0.68x | 1.54x | NT$-20.32 Million |
| 2019 | -82.75% | -74.31% | 0.59x | 1.89x | NT$-178.35 Million |
| 2020 | -40.26% | -26.70% | 0.83x | 1.81x | NT$-69.29 Million |
| 2021 | -60.65% | -31.77% | 0.97x | 1.96x | NT$-60.63 Million |
| 2022 | -33.16% | -10.55% | 1.29x | 2.45x | NT$-27.83 Million |
| 2023 | 8.79% | 2.41% | 1.35x | 2.70x | NT$-853.50K |
| 2024 | 31.24% | 10.03% | 1.24x | 2.50x | NT$21.75 Million |
Industry Comparison
This section compares Sea Mild Biotechnology Co., Ltd.'s net assets metrics with peer companies in the Household & Personal Products industry.
Industry Context
- Industry: Household & Personal Products
- Average net assets among peers: $2,220,549,500
- Average return on equity (ROE) among peers: 4.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sea Mild Biotechnology Co., Ltd. (7516) | NT$107.64 Million | -23.41% | 1.62x | $4.01 Million |
| Farcent Enterprise Co Ltd (1730) | $1.11 Billion | 10.36% | 0.53x | $50.96 Million |
| Mao Bao Inc (1732) | $464.20 Million | 5.44% | 0.28x | $15.99 Million |
| Taiyen Biotech Co Ltd (1737) | $6.57 Billion | 3.19% | 0.05x | $103.31 Million |
| Sanitar Co Ltd (1817) | $1.49 Billion | 15.47% | 0.23x | $56.41 Million |
| Shihlin Paper Corp (1903) | $4.58 Billion | 0.00% | 0.72x | $268.57 Million |
| Jia Wei Lifestyle Inc (3557) | $778.16 Million | -13.00% | 0.45x | $39.15 Million |
| Chlitina Holding Ltd (4137) | $4.11 Billion | 29.63% | 0.55x | $176.21 Million |
| Jourdeness Group Ltd (4190) | $1.77 Billion | -16.49% | 3.17x | $20.26 Million |
| Kuangli Photoelectric Technology Co Ltd (6431) | $398.69 Million | -4.73% | 0.12x | $39.19 Million |
| Nan Liu Enterprise Co Ltd (6504) | $929.70 Million | 15.00% | 2.02x | $37.29 Million |